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1. Introduction 
Two sequences differing in the amino acids at 
3 positions have been reported for the (1-34)N-ter- 
minal fragment of human parathyroid hormone by 
Brewer et al. [ 1,2] and subsequently by Niall et al. 
[3,4] (fig.1). These two structures have been shown 
to be biologically active in both in vivo and in vitro 
assay systems [S-9] . Nevertheless due to the different 
assay conditions used in these studies, it is at present 
difficult to assess the relative biological activities of 
the two sequences. We have reported a comparative 
study of their relative biological activities in the in vitro 
renal cortical adenylate cyclase activation assay system 
[lo]. The Niall sequence was shown to be more active 
than the Brewer sequence on bovine and porcine 
kidney membranes. Nevertheless this study as well as 
others [9,11,12] showed also that the biological 
response depends on the species origin of the mem- 
brane. Thus in order to further assess the relative 
biological activities of these two hormone sequences 
we studied their relative biological potency in the 
same, isologous in vitro assay system using human 
kidney membranes and compared them with a 
glandular extract of human parathyroid. Our results 
show unambiguously that the behaviour of the Niall 
sequence is very close to that of the natural glandular 
extract and suggest hat this sequence is more likely 
the active natural hormone. 
2. Materials and methods 
2.1. Hormones 
2.1 .l . Synthetic fragments 
Solid phase synthesis of (1-34)N-terminal frag- 
ment of the human parathyroid hormone according 
to the sequence of Brewer et al., hPTH(l-34)B, and 
of Niall et al., hPTH(l-34)Nl, was carried out by 
the Merrifield procedure [ 131. Benzylhydrylamine 
hPTHs t$N@Val Ser GlU tie Gln@&i His Asn Leu Cly LyS HiS Leu@ Ser~Clu Arg ValmTrp Leu Arg Lys Lys@Gln!$Val HIS Asn Phe-COOd 
1 5 10 IS 
hPTH,., H2NEVal Scr Clu Ile Gln~Met His Asn Leu Gly Lys His Leubj Ser@Glu 
1 5 10 15 
bPTH H$@Val Ser Glu Ile Gln@let His Am Leu Gly Lys His LeaSermGlu 
1 5 18 15 m 25 30 34 
F&. 1. Amino acid sequences of the (I-34)NH,-terminal residues of parathyroid hormone: hPTHB = human sequence of Brewer 
et al.; hPTHN = human sequence of Nlall et al.; bPTH = bovine sequence. (a) Our synthesized hPTHB and hPTHN were analogues 
with carboxyl-terminal amide at position 34. (b) Brewer revised sequence’ Gin [2]. 
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resin was used giving a terminal amide in the final hPTH concentrations as well as of the basal xtlvify. 
peptide [I 4,151. Details of the synthetic procedure Assay of basal and newly formed cyclic AMP was 
and purification steps have been reported [IO]. Frag- 
/ 
, perforined by a competitive protem binding assay [I 91. 
Comparisons of hormone products were studied in 
the same experiments and under identical conditions. 
ments were shown to have the theoretical composi- 
tion by amino acid analysis and the peptides were 
shown to be homogeneous by complete sequence 
analysis and repetitive Edman degradation, Purity of 
the synthesized fragments was estimated to be >80%. 
In addition a synthetic fragment corresponding to the 
Niall sequence, hPTH(l-34)NZ. was obtained from 
Armour (jot no. K80017-F). (1-34fN-terminal 
synthetic fragment of bovine parathyroid hormone, 
bPTH(f -34)*, was obtained from Beckman-Bio- 
product (lot no. 10824). 
22.2. Native hPTH 
Native hPTH was prepared from pooted human 
parathyroid adenomas obtained from surgical proce- 
dures, Due the limited availibility of these tissues, it 
was not possible to carry out an extraction procedure 
followed by a complete purification process. Thus we 
prepared a crude extract containing hPTH. Never- 
theless, in order to eliminate as far as possible inter- 
ference in our assay system by chemical interactions 
and/or due to the heterogeneity of our preparation 
which could confuse interpretation of the data, we 
prepared glandular extracts by two extraction proce- 
dures: the urea-HCl method [ 11, hPTH extract I, 
and the phenol procedure [ 161, hPTH extract II. 
2.3. Hunm cortical kidrley adettylate cyclase assay 
Human cortical membranes were isolated from 
normal human kidneys using the procedure in [lo] , 
The final membrane preparations showed an 8-l O- 
fold increase in the specific activity of adenylate 
cycfase. Total adenosine triphosphatase activity was 
enriched S--7-fold. Results of other enzymatic 
marker studies specific for various intraceIlular orga- 
nelles showed that these were largely eliminated by 
the purification procedure. 
Adenylate cyclase assay was performed using a 
standard procedure with an ATP regenerating system 
[17] but with 2.5 X 10e3 M ATP and 4.5 X 10e3 M 
Mg’*. In order to obtain full activation of adenylate 
cyclase, lo4 M GTP final concentration was added 
[ 181 giving a 2-fold increase over the whole range of 
* This fragment contains glutamic acid at sequence position 22 
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3. Results 
3 .l . Biological activity of hPTH extract I atzd II 
The two hormones extracted from glandular tissues 
give the same dose-response curves (fig.?). Although 
hPTH extract I gives activation which is slightly higher 
than obtained with hPTH extract II, fig.2 sEows that 
the 2 extraction procedures give products whose 
activity is similar. The differences in biological activity 
coutd reflect differences in purity of these 2 extracts 
which are both at only a very early stage in the purifi- 
catin procedure. Thus hPTH extract I and II are prod- 
ucts which are both acceptable for comparing the 
potency of hPTH(l--34)B and hPTH(l-34)N. 
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Fig.2. Dose--response curves for hPTH( I-34)B and 
hPTH(I--34)N in comparison with glandular extracts of 
hPTH and bPTH(l-34) in the human renal cortical 
adenylate cyclasc assay. Each point represents the mean of 
4-6 determinations ?- SFM.~denotes half-maximal 
response. 
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3.2. Relative biological activity of hPTH(I -34)B and 4. Conclusions 
hPTH(l-34)N 
hPTH(l-34)N whether synthesized in our labora- 
tory (N 1) or obtained from Armour (N?) is able to 
activate human renal cortical adenylate cyclase and 
gives the same pattern of activation as hPTH extract I 
or II (fig.2). Maximal activities are similar 
(9500-10 500 pmol cyclic AMP produced in 15 min/ 
mg protein) and the linear part of the dose-response 
curves are parallel. 
In the same experimental conditions hPTH(l-34)B 
also activates human kidney membranes (fig.2). 
Nevertheless the dose-response curve is not parallel 
to and the maximal activity is very inferior 
(4000 + 150 pmol cyclic AMP produced in 15 min/mg 
protein) to that obtained with WTH extracts. To 
eliminate the possible presence of a contaminant in 
our hPTH(l-34)B which could act as an inhibitor of 
the adenylate cyclase activation process, both 
hPTH( l -34)N and bPTH( l-34) were incubated in 
the presence and absence of hPTH(l-34)B. The pres- 
ence of hPTH(l-34)B did not significantly diminish 
the cyclic AMP produced (table 1). 
Previous studies [9- 121 have shown that in vitro 
biological activity as measured by activation of renal 
cortical adenylate cyclase membranes depends on the 
species origin of the membranes. In the present study 
using human kidney membranes and glandular extracts 
containing hPTH, we show that the Niall sequence is, 
at least in this in vitro assay system, a product which 
is more potent and activates human kidney membranes 
with dose-response curves which are closer to the 
native product than is the Brewer sequence. 
Furthermore bPTH(l -34) and hPTH(l-34)N 
which differ only in the amino acids in 3 positions, as 
compared to 6 for hPTH(l-34)B (fig.l), give very 
similar activation patterns. 
Half-maximal stimulations (app. K, values) were, 
respectively, 1.28 pg/ml(3.1 X 10e7 M) for 
hPTH(l-34)Nl and 40 pg/ml(9.8 X 10m6 M) for 
hPTH(l-34)B. Results obtained with hPTH( l-34)Nl 
and hPTH(l-34)N2 were very similar: the K, value 
for N2 was 1.20 /*g/ml (2.9 X 10m7 M). 
Although obviously it cannot be inferred from 
our studies that the Niall sequence is the ‘true’ 
sequence, our results suggest hat this sequence is 
more likely the active natural product. Other results 
concerning their relative immunological properties 
support this hypothesis [20]. Nevertheless arguments 
about the existence of isohormones or the conforma- 
tional properties of hPTH (discussed [9,20] ) cannot 
be eliminated. It seems, however, that the present 
available data justify using the Niall sequence rather 
than the Brewer sequence for evaluating physiological 
properties of hPTH. 
Figure 2 clearly shows that bPTH( l-34) behaves 
in a manner much more similar to hPTH(l-34)N 
than to hPTH(l-34)B. 
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+ hPTH(l-34)B (100 &ml) 11050+ 1020 90-110 
+ hPTH(1&34)B (300 fig/ml) 11 240 f 1230 88-112 
hPTH(1 -34)N and bPTH(l-34) at submaximal concentrations were incubated in 
the presence of hPTH(l-34)B at 2 concentrations (submaximal and large excess) 
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